First migraine drug to both block, tackle headaches ‘shifts paradigm’ of treatment
Fox News
Most of Lilly Rockwell’s earliest memories from childhood are plagued with severe headaches to the point of vomiting. Her migraine disease worsened into adulthood as she worried over the impact on her career as a real estate agent, and quality time with family and friends.
Biohaven's findings for its late-stage trial of rimegepant, a calcitonin gene-related peptide receptor antagonist, were published in The Lancet, and according to a company release, the drug dropped migraine days by 30% after a week when taken every other day while about half of participants saw at least a 50% decline in moderate-to-severe migraine days at three months. The drug works by blocking a receptor associated with the cause of migraines. For Rockwell, she reports significantly more migraine-free days. "I was able to focus more time and energy on my career helping people find their dream homes and my social life," she wrote in an email. "I could enjoy more of the little things in life, and I felt for the first time what it's like to live as a person who doesn't get migraines."More Related News